CohBar Inc. (CWBR)’s Financial Results Comparing With Oragenics Inc. (NYSEAMERICAN:OGEN)

CohBar Inc. (NASDAQ:CWBR) and Oragenics Inc. (NYSEAMERICAN:OGEN) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CohBar Inc. N/A 0.00 14.35M -0.35 0.00
Oragenics Inc. N/A 0.00 10.03M -1.45 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 represents CohBar Inc. (NASDAQ:CWBR) and Oragenics Inc. (NYSEAMERICAN:OGEN)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
CohBar Inc. 0.00% -96.8% -80.6%
Oragenics Inc. 0.00% 0% -119.9%

Risk & Volatility

CohBar Inc. has a beta of 1.06 and its 6.00% more volatile than Standard and Poor’s 500. Oragenics Inc.’s 3.00% more volatile than Standard and Poor’s 500 which is a result of the 1.03 beta.

Liquidity

CohBar Inc. has a Current Ratio of 33.2 and a Quick Ratio of 33.2. Competitively, Oragenics Inc.’s Current Ratio is 9.9 and has 9.9 Quick Ratio. CohBar Inc.’s better ability to pay short and long-term obligations than Oragenics Inc.

Institutional & Insider Ownership

Institutional investors owned 9.6% of CohBar Inc. shares and 13.1% of Oragenics Inc. shares. About 4.5% of CohBar Inc.’s share are owned by insiders. Comparatively, 1.1% are Oragenics Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CohBar Inc. -12.47% -9.37% -24.31% -61.17% -22.17% -27.97%
Oragenics Inc. -26.67% -2.94% 135.6% -34.43% -69.16% -57.85%

For the past year CohBar Inc. has stronger performance than Oragenics Inc.

Summary

CohBar Inc. beats Oragenics Inc. on 4 of the 6 factors.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.